

Daniele Pastori

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/649549/daniele-pastori-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223
papers

4,365
citations

36
h-index

55
g-index

286
ext. papers

5,891
ext. citations

5.2
avg, IF

6.01
L-index

#	Paper	IF	Citations
223	REPLY to "Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome".. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1	1
222	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry.. <i>Platelets</i> , 2022 , 1-6	3.6	
221	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. <i>Lancet, The</i> , 2022 , 399, 1383-1390	40	9
220	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study.. <i>Journal of Autoimmunity</i> , 2022 , 129, 102832	15.5	
219	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk: Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , 2022 , 12, 785	3.6	
218	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.. <i>Thrombosis Journal</i> , 2021 , 19, 102	5.6	0
217	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 779503	5.4	2
216	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , 2021 , 1	5	3
215	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , 2021 , 209, 69-74	8.2	3
214	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021 , 345, 7-13	3.2	13
213	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , 2021 , 23, E184-E188	1.5	3
212	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021 , 16, 2063-2068	3.7	2
211	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the CHEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , 2021 , 10, e017519	6	6
210	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021 , 26,	4.8	4
209	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021 , 165, 105418	10.2	7
208	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients 2021 , 10,		1
207	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 700-702	7	

206	The Atrial Fibrillation Better Care (ABC) pathway in atrial fibrillation: a systematic review and meta-analysis of 285,000 patients. <i>Europace</i> , 2021 , 23,	3.9	1
205	Adherence to the Atrial Fibrillation Better Care Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	45
204	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2021 , 168, 1-5	7.8	0
203	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021 , 66, 28-36	8.5	4
202	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102821	13.6	3
201	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	5
200	Time to hospitalisation, CT pulmonary involvement and in-hospital death in COVID-19 patients in an Emergency Medicine Unit. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14426	2.9	1
199	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021 , 12, 695961	5.6	1
198	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
197	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
196	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 379-387	3.7	13
195	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2021 , 46, 100410	17.1	5
194	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021 , 322, 245-249	3.3	3
193	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13771	2.9	3
192	Anticoagulation in patients with advanced liver disease: an open issue. <i>Internal and Emergency Medicine</i> , 2021 , 16, 61-71	3.7	3
191	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021 , 141, 1-6	3	2
190	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 658-665	6.4	10
189	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021 , 327, 176-182	3.2	5

188	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f11-f19	6.4	10
187	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14064	2.9	1
186	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1583-1591	3.7	5
185	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2683-2684	6.9	0
184	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021 , 127, 2122-2129	6.4	8
183	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. <i>Digestive and Liver Disease</i> , 2021 , 53, 383-384	3.3	5
182	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021 , 85, 80-85	3.9	6
181	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , 2021 , 13,	6.7	3
180	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 715878	5.4	5
179	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , 2021 ,	3.9	1
178	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
177	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2904-2911	4.5	6
176	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 698008	5.6	4
175	The challenge of cardiovascular prevention in NAFLD. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 877-878	18.8	3
174	Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial". <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 699-701	2.1	
173	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. <i>Journal of Cardiology</i> , 2021 , 78, 368-374	3	0
172	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , 2021 , 22, 434-444	2.7	2
171	The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors. <i>Antioxidants</i> , 2021 , 10,	7.1	15

170	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021 , 50, 245-261	3.2	12
169	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2455-2463	3.8	14
168	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , 2020 , 126, 1415-1442	15.7	14
167	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 866-875	7	27
166	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , 2020 , 15, 755-758	3.7	12
165	Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis. <i>Hemodialysis International</i> , 2020 , 24, 383-396	1.7	1
164	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
163	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020 , 12,	6.7	17
162	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020 , 127, 400-401	15.7	43
161	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020 , 105, 562-572	6.6	43
160	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. <i>International Journal of Cancer</i> , 2020 , 147, 3424-3430	7.5	6
159	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , 2020 , 4, 1034-1040	6	16
158	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00116	4.2	5
157	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020 , 190, 588-593	4.5	6
156	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00123	4.2	11
155	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 949-956	7	129
154	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , 2020 , 152, 355-362	7.8	8
153	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 355-360	5.1	8

152	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2324-2331.e4	6.9	68
151	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 513-520	6.4	5
150	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. <i>Hepatology</i> , 2020 , 72, 470-485	11.2	90
149	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620945792	3.3	5
148	Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. <i>American Journal of Cardiology</i> , 2020 , 132, 72-78	3	3
147	Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008477	6.4	0
146	Clinical and pharmacological characteristics of elderly patients admitted for bleeding: impact on in-hospital mortality. <i>Annals of Medicine</i> , 2020 , 52, 413-422	1.5	3
145	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1291-1298	5.3	8
144	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13378	4.6	74
143	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. <i>Clinical and Translational Science</i> , 2020 , 13, 1071-1076	4.9	22
142	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020 , 12,	6.7	31
141	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , 2020 , 8,	4.8	4
140	Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2020 , 109, 96-102	6.1	22
139	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , 2020 , 15, 135-143	3.7	9
138	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , 2020 , 9,	7.1	11
137	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019 , 124, 1662-1668	3	15
136	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019 , 183, 28-32	8.2	8
135	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 576-585	7	6

134	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019 , 124, 723-728	3	7
133	Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2019 , 14, 1199-1201	3.7	1
132	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 561-576	4.3	10
131	Statins and non-alcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 1787	7.9	3
130	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2019 , 292, 126-130	3.2	12
129	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , 2019 , 18, 519-525	13.6	22
128	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 17	5.4	4
127	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , 2019 , 163, 111-118	6	11
126	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , 2019 , 58, 843-851	5.2	18
125	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 2301-2308	7.9	11
124	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , 2019 , 289, 195-200	3.1	8
123	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , 2019 , 31, 786-790	8.4	3
122	Off-label use of ceftaroline fosamil: A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 562-571	14.3	17
121	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2436	15.1	
120	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e012596	6	13
119	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2019 , 25, 4172-4180	5.6	13
118	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , 2019 , 6, 001180	1.2	0
117	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1034-1041	6.1	13

116	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 91-98	4.7	22
115	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 508-515	3.8	14
114	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1261-1267	6.4	57
113	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019 , 132, 856-861	2.4	39
112	A Simple Clinical Risk Score (CHEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects. <i>Chest</i> , 2019 , 155, 510-518	5.3	64
111	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. <i>Sleep Medicine</i> , 2018 , 43, 66-70	4.6	47
110	Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. <i>Scientific Reports</i> , 2018 , 8, 3598	4.9	50
109	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. <i>Scientific Reports</i> , 2018 , 8, 3702	4.9	40
108	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018 , 54, 34-39	3.9	14
107	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2018 , 107, 772-777	6.1	19
106	Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation. <i>Nutrition</i> , 2018 , 55-56, 36-40	4.8	10
105	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018 , 261, 92-98	3.2	24
104	Reply: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient?. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 706-707	15.1	
103	Reply. <i>Gastroenterology</i> , 2018 , 154, 761-762.e1	13.3	2
102	Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 1129-1132	4.3	6
101	Severity of OSAS, CPAP and cardiovascular events: A follow-up study. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12908	4.6	18
100	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 255, 69-73	3.2	17
99	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 537-541	8.5	7

98	Response to Duret et al. <i>American Journal of Gastroenterology</i> , 2018 , 113, 775-776	0.7	
97	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , 2018 , 274, 29-34	3.1	9
96	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018 , 132, 149-159	10.2	7
95	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018 , 50, 288-302	1.5	10
94	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018 , 13, 651-660	3.7	9
93	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018 , 200, 32-36	4.9	11
92	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , 2018 , 17, 830-836 ^{1,2}		5
91	Aging and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. <i>Journal of Nutrition, Health and Aging</i> , 2018 , 22, 73-81	5.2	10
90	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018 , 50, 511-518	1.5	7
89	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018 , 82, 1286-1292	2.9	3
88	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	4
87	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , 2018 , 76, 713-722	0.9	83
86	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , 2018 , 7, e009509	6	6
85	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	19
84	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818793561	4.7	21
83	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , 2018 , 264, 58-63	3.2	50
82	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , 2018 , 35, 1134-1135	3.5	1
81	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 88-95	3.8	54

80	Carotid plaque detection improves the predictive value of CHADS-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017 , 231, 143-149	3.3	16
79	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disease progression by aspirin in diabetic patients (LEDA) trial. Rationale and study design. <i>American Heart Journal</i> , 2017 , 189, 120-127	4.9	6
78	Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017 , 153, 480-487.e1	13.3	207
77	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 890-895	4.5	19
76	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , 2017 , 7, 3797	4.9	7
75	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	60
74	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017 , 262, 179-184	3.1	14
73	Reply to: "Monitoring antithrombotic K anticoagulants in antiphospholipid syndrome: A challenge in quality". <i>Atherosclerosis</i> , 2017 , 256, 148-149	3.1	
72	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1832-1839	0.7	67
71	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017 , 27, 1083-1124	8.4	66
70	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1159-1165	3.7	11
69	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1455-1462	15.1	39
68	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , 2017 , 10, 1005-1022	2.8	2
67	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. <i>Scientific Reports</i> , 2017 , 7, 15756	4.9	34
66	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 161-167	4.5	32
65	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1558-1570	7	36
64	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2016 , 223, 619-624	3.2	11
63	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016 , 25, 751-755	8.4	9

62	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016 , 36, 74-80	3.9	11
61	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	34
60	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016 , 73, 107-14	18.9	32
59	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review. <i>Medicine (United States)</i> , 2016 , 95, e2895	1.8	33
58	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016 , 8, 275-83	2.1	26
57	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016 , 11, 199-204	3.7	30
56	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , 2016 , 202, 934-5	3.2	
55	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016 , 244, 48-50	3.1	13
54	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , 2016 , 7, 39143-39147	3.3	10
53	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 856-63	7	26
52	Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F in HIV-1 patients on abacavir-based therapies. <i>HIV Medicine</i> , 2016 , 17, 774-777	2.7	
51	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	102
50	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016 , 113, 484-489	10.2	18
49	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015 , 26, e31-3	3.9	2
48	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. <i>Nutrition and Diabetes</i> , 2015 , 5, e172	4.7	57
47	Response to "Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality". <i>International Journal of Cardiology</i> , 2015 , 189, 247-8	3.2	
46	Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. <i>American Journal of Cardiology</i> , 2015 , 115, 1402-6	3	20
45	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , 2015 , 23, 682-7	8.4	41

44	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , 2015 , 120, 50-5	3.7	29
43	Obstructive Sleep Apnea and the Metabolic Syndrome: Pathophysiological and Clinical Evidence 2015 , 177-184		
42	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e113	4.2	17
41	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta: Refers to Sevket Balta, MD et al. <i>International Journal of Cardiology</i> , 2015 , 201, 225-6	3.2	
40	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015 , 2, 750-4	8.8	41
39	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015 , 201, 513-6	3.2	50
38	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015 , 34, 899-903	5.9	22
37	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015 , 180, 1-5	3.2	30
36	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015 , 179, 139-43	3.2	18
35	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 617-24	7	38
34	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 28014-21	6.3	13
33	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015 , 7, 1325-36	3.4	116
32	Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. <i>Chest</i> , 2015 , 147, 1644-1650	5.3	53
31	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , 2015 , 70, 651-8	18.9	17
30	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015 , 5, e008026	3	17
29	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015 , 116, 647-51	3	88
28	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015 , 17, 1223-8	3.9	12
27	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015 , 170, 490-7.e1	4.9	22

26	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015 , 70, 961-6	7.3	33
25	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015 , 47, 4-11	3.3	99
24	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets. <i>Current Pharmaceutical Design</i> , 2015 , 21, 5945-50	3.3	4
23	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. <i>Internal and Emergency Medicine</i> , 2014 , 9, 123-31	3.7	30
22	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. <i>Europace</i> , 2014 , 16, 1107-16	3.9	35
21	Platelet activation is associated with myocardial infarction in patients with pneumonia. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1917-25	15.1	105
20	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. <i>Atherosclerosis</i> , 2014 , 235, 649-58	3.1	51
19	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. <i>Trends in Cardiovascular Medicine</i> , 2014 , 24, 142-8	6.9	22
18	Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia?. <i>Antioxidants and Redox Signaling</i> , 2014 , 20, 2949-54	8.4	22
17	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. <i>European Journal of Internal Medicine</i> , 2014 , 25, 566-70	3.9	17
16	Modern approach to the clinical management of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8341-50	5.6	52
15	Total adiponectin is inversely associated with platelet activation and CHADSEVASC score in anticoagulated patients with atrial fibrillation. <i>Mediators of Inflammation</i> , 2014 , 2014, 908901	4.3	13
14	Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2014 , 7, 1112	0.8	14
13	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013 , 168, 3241-7	3.2	9
12	Vitamin e serum level, a new tool to stratify bleeding risk in patients receiving oral anticoagulant therapy. <i>European Heart Journal</i> , 2013 , 34, P534-P534	9.5	
11	Vitamin e serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Heart Journal</i> , 2013 , 34, P5606-P5606	9.5	
10	Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. <i>Journal of the American Heart Association</i> , 2013 , 2, e000364	6	27
9	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. <i>American Journal of Hematology</i> , 2012 , 87, 384-7	7.1	23

8	Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. <i>Circulation</i> , 2012 , 126, 92-103	16.7	115
7	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , 2012 , 98, 1063-6	5.1	24
6	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. <i>BMC Infectious Diseases</i> , 2011 , 11, 341	4	5
5	Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. <i>AIDS Research and Therapy</i> , 2011 , 8, 9	3	1
4	Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 1766-71	9.4	31
3	Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review. <i>International Reviews of Immunology</i> , 2011 , 30, 44-66	4.6	5
2	Undifferentiated connective tissue disease - an unsolved problem: revision of literature and case studies. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 271-8	3	8
1	Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals. <i>Aids</i> , 2009 , 23, 2233-4	3.5	2